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Abstract
Background: DNA methylation of the Th1 and Th2 cytokine genes is altered during cow’s milk allergy (CMA).
Forkhead box transcription factor 3 (FoxP3) is essential for the development and function of regulatory T cells
(Tregs) and is involved in oral tolerance acquisition. We assessed whether tolerance acquisition in children with
IgE-mediated CMA is associated with DNA demethylation of the Treg-specific demethylated region (TSDR) of FoxP3.
Results: Forty children (aged 3–18 months) were enrolled: 10 children with active IgE-mediated CMA (group 1), 10
children who outgrew CMA after dietary treatment with an extensively hydrolyzed casein formula containing the
probiotic Lactobacillus rhamnosus GG (group 2), 10 children who outgrew CMA after treatment with other formulas
(group 3), and 10 healthy controls (group 4). FoxP3 TSDR demethylation and expression were measured in
mononuclear cells purified from peripheral blood of the four groups of children. FoxP3 TSDR demethylation was
significantly lower in children with active IgE-mediated CMA than in either children who outgrew CMA or in
healthy children. Formula selection influenced the FoxP3 TSDR demethylation profile. The FoxP3 TSDR
demethylation rate and expression level were correlated.
Conclusions: Tolerance acquisition in children with IgE-mediated CMA involves epigenetic regulation of the FoxP3
gene. This feature could be a new target for preventive and therapeutic strategies against CMA.
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Background
Epigenetic mechanisms have been implicated in the patho-
genesis of food allergy [1]. We previously demonstrated
that tolerance acquisition in children with IgE-mediated
cow’s milk allergy (CMA) is driven by epigenetic modula-
tion of the Th1 and Th2 cytokine genes [2]. A regulatory T
cell (Treg) suppressive phenotype, characterized by stable
expression of the transcription factor “Forkhead box Pro-
tein 3” (FoxP3), plays a pivotal role in food tolerance [3–7].
FoxP3 messenger RNA (mRNA) expression is lower in
children with atopic asthma or IgE-mediated food allergy
than in healthy children [8]. FoxP3 stable expression re-
quires full CpG demethylation of its transcriptional
regulatory regions [9, 10], and, moreover, hypermethylation
of the FoxP3 gene has been associated with reduced Treg
function and allergy [7, 11].
DNA methylation is a biologically and chemically
stable epigenetic modification that locks in long-term
gene expression patterns [12, 13]. The demethylation
status of FoxP3 at a highly conserved region within the
Treg-specific demethylated region (TSDR), a CpG-rich
region, located on the 2nd conserved non-coding
sequence of FoxP3 (CNS2), is restricted to Tregs [14, 15].
Transcriptional activity of the TSDR is essentially deter-
mined by its methylation status: it is completely inactive
in its methylated state, but when the TSDR is demethy-
lated, transcription factors such as Ets-1 and Creb can
bind to the TSDR [16] TSDR demethylated and open
chromatin conformation in the Foxp3 locus leads to stable
phenotype differentiated Foxp3+ Treg [17, 18]. FoxP3
TSDR demethylation in peripheral blood mononuclear
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cells (PBMCs) has been associated with reduced atopic
sensitization and asthma in children [19]. Epigenetic regu-
lation of antigen-induced T cell subsets may predict a state
of immune tolerance in food allergy. Indeed, DNA methy-
lation of the FoxP3 gene in Tregs decreased during oral
tolerance acquisition in patients with peanut allergy
undergoing oral immunotherapy [19]. The aim of this
study was to evaluate further the epigenetic regulation of
FoxP3 gene in children with IgE-mediated CMA.
Methods
Study subjects
We evaluated IgE-mediated CMA children (aged 3 to
18 months) consecutively referred to our tertiary Pediatric
Allergy Center for oral food challenge. Oral food challenge
was requested to obtain a diagnosis because of recent
evidence of CMA signs and symptoms (“active CMA
patients”; group 1) or to investigate the occurrence of oral
tolerance acquisition after dietary treatment with an ex-
tensively hydrolyzed casein formula containing the pro-
biotic Lactobacillus rhamnosus GG (LGG, 1 × 106/ml
CFU) (“subjects who outgrew CMA with extensively hy-
drolyzed casein formula (EHCF) + LGG”; group 2) or with
other formulas (“subjects who outgrew CMA with other
formulas”; group 3). All patients underwent a double-
blind placebo-controlled oral challenge (DBPCFC), as de-
scribed previously [20]. All oral food challenges took place
at our Center on two separate days with a 1-week interval.
Parents of children taking antihistamine were advised to
withhold these medications for at least 72 h before and
during the challenge. Randomization and preparation of
the challenges were performed by experienced food allergy
dieticians not directly involved in the procedures. Briefly,
every 20 min, successive doses (0.1, 0.3, 1, 3, 10, 30, and
100 ml) of fresh pasteurized cow’s milk containing 3.5 %
fat (verum) or hypoallernic or soy formula that the child
was already consuming (placebo) were administered. Full
emergency equipment and medications (epinephrine, anti-
histamines, and steroids) were available. The results were
assessed simultaneously by three experienced pediatric al-
lergists. Study subjects were scored for nine items divided
into four main categories: (i) general (lowered blood pres-
sure plus tachycardia); (ii) skin (rash, urticaria/angio-
edema); (iii) gastrointestinal (nausea/repeated vomiting,
crampy-like abdominal pain, diarrhea); and (iv) respiratory
(sneezing/itching, nasal congestion/rhinorrhea, stridor de-
riving from upper airway obstruction or wheezing) on a 0-
to 3-point scale (0, none; 1, light; 2, moderate; and 3, se-
vere). If at least two of the three physicians independently
scored any item at level 3, or 2 (or more) items at level 2,
the test result was considered positive. Clinical symptoms
occurring within 2 h of administering the highest dose
were defined as “IgE-mediated reactions.” The infants
were observed for 2 h after the final dose and then
discharged. In the case of a positive DBPCFC, at any test-
ing dose, the patient remained under observation until
symptom resolution. If the patient did not show any
symptom within the first 24 h, parents were advised to
give one single feed of 100 ml of the tested formula
(verum or placebo) everyday at home for 7 days. If any
symptom occurred during this period, the patient
returned to the outpatient clinic on the same day. After
7 days of verum or placebo administration, the patients
were examined and the parents interviewed at the Center.
To rule out a false-negative challenge result, parents were
asked to contact the Center if any symptoms occurred in
the 7 days after the DBPCFC procedures. The challenge
was considered negative if the patient tolerated the entire
challenge, including the observation period. Clinical toler-
ance acquisition was defined by the presence of a negative
DBPCFC. Patients with a negative oral challenge (groups
2 and 3) were reassessed 4 weeks later to verify persistence
of clinical tolerance. A venous blood sample (4 ml) was
obtained from all patients after oral challenge.
Exclusion criteria were as follows: allergic disorders or
food allergies other than CMA, eosinophilic disorders of
the gastrointestinal tract, food protein-induced enterocoli-
tis syndrome, concomitant chronic systemic diseases, con-
genital cardiac defects, active tuberculosis, autoimmune
diseases, immunodeficiency, chronic inflammatory bowel
diseases, celiac disease, cystic fibrosis, metabolic diseases,
lactose intolerance, malignancy, chronic pulmonary dis-
eases, and malformations of the gastrointestinal tract. Dur-
ing the same study period, consecutive healthy children,
not at risk of atopic disorders (namely, those without a
first-degree relative affected by an atopic disorder), attend-
ing our Center because of minimal surgical procedures
served as a control group (group 4).
A venous blood sample (4 ml) was collected also from
these healthy subjects. They were assessed for the
presence of food allergy and other allergic diseases at
enrollment and 6 months after blood sampling by
pediatric allergists at our Center.
Total IgE and specific IgE against proteins and epitopes
of cow’s milk
Serum was obtained by centrifugation for 10 to 15 min.
Serum was flash frozen and stored at −80 °C until ana-
lysis. Serum total IgE and specific IgE against epitopes of
cow’s milk (alpha-lactalbumin, beta-lactoglobulin, bovine
serum albumin, casein, lactoferrin) were analyzed by
enzymatic immunoassay (Phadia 100 ThermoFisher
Scientific CAP system, Rodano Milano, Italy). Results
were expressed as kilounits per liter (kU/l).
DNA methylation and mRNA expression
Peripheral blood mononuclear cells were isolated
from whole blood samples using the Ficoll-Paque
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(Sigma-Aldrich, St. Louis, MO, USA) method, as
described previously [2]. The primers used for DNA
methylation analysis of FoxP3 TSDR are reported
elsewhere [15]. High-resolution melting real-time PCR
for methylation analysis was performed as described
previously [2]. The results of methylation analysis
were verified by direct sequencing (using the Sanger
method modified as follows: ddNTPs labeled with
four different fluorophores) and analyzed by capillary
electrophoresis (the analytical specificity and sensitivity of
the test was >99 %). Real-time PCR was performed with
the LightCycler® 480 instrument (Roche Applied Science,
Penzberg, Germany) using 96-well plates (Roche Applied
Science). Briefly, RNA was extracted from the PBMCs of
the four study groups using the Trizol protocol (Invitro-
gen, Life Technologies Europe BV, Monza, Italy), as previ-
ously described [2]. The concentration and purity of RNA
samples were measured and verified by NanoDrop 1000
spectrophotometry (Thermo Scientific, Wilmington, DE,
USA). For complementary (cDNA) synthesis, 1 μg total
RNA was transcribed with a High Capacity cDNA Reverse
Transcription kit (Applied Biosystems, Foster City,
CA, USA) according to the manufacturer’s instruc-
tions. The 10-μl reaction volumes contained 1 μl tem-
plate, 10 μl SYBR Green (Applied Biosystems), and
5 μM primers (FoxP3 forward primer 5′-AGCTGGA
GTTCCGCAAGAAAC-3′; FoxP3 reverse primer 5′-
TGTTCGTCCATCCTCCTTTCC-3′; GenBank Acces-
sion number NC_000023.11). Quantitative real-time
amplifications were performed in triplicate with an
initial incubation at 95 °C for 30 s, followed by 40 cy-
cles of 95 °C for 10 s and 60 °C for 30 s, using a Light
Cycler 79 HT (Applied Biosystems). The quantitative
gene expression was calculated with the comparative
Ct method and normalized against the Ct of glucuroni-
dase (GUS) messenger as reference gene.
Statistical analysis
The Kolmogorov-Smirnov test was used to determine
whether variables were normally distributed. The χ2 test
and Fisher’s exact test were used for categorical variables.
We used the t test and one-way ANOVA to evaluate differ-
ences among continuous variables. To determine which
groups in the sample differ, the Bonferroni correction was
performed. Pearson’s correlation coefficient “r” was used to
evaluate the correlation between continuous variables. The
level of significance for all statistical tests was two-
sided, P < 0.05. All analyses were conducted by a statis-
tician blinded to patient group assignment, using SPSS,
version 19.0 for Windows (SPSS Inc., Chicago, IL, USA).
Results
The main demographic and clinical characteristics of the
study population are reported in Table 1. The 10 children
affected by CMA in group 1 had a positive DBPCFC at
doses between 3 and 10 ml of cow’s milk. The 20 CMA
children with recent evidence of oral tolerance acquisition,
demonstrated by a negative DBPCFC (groups 2 and 3),
were able to consume at least one full cup/day of cow’s
milk without symptoms. Group 2 patients received EHCF
Table 1 The main demographic and clinical characteristics of the four study groups
Subjects with CMA
at diagnosis
Subjects outgrown CMA Healthy
subjectsEHCF + LGG Other formulas
Group 1 Group 2 Group 3 Group 4
Number 10 10 10 10
Male, number (%) 7 (70) 7 (70) 6 (60) 4 (40)
Age, months (SD) 5.5 (0.7) 16.9 (0.9) 17 (0.9) 9 (4)
Body weight, kg (SD) 7.385 (964.7) 12.047 (682.4) 12.273 (776.7) 8.075 (3193.5)
Spontaneous delivery, number (%) 5 (50) 2 (20) 3 (30) 4 (40)
Breastfeeding, ≤8 weeks, number (%) 10 (100) 10 (100) 10 (100) 10 (100)
Symptoms at the CMA onset
Gastrointestinal, n (%) 4 (40) 5 (50) 3 (30) –
Cutaneous, n (%) 8 (80) 8 (80) 7 (70) –
Respiratory, n (%) 1 (10) 3 (30) 3 (30) –
Total serum IgE, kU/l (SD) 260.6 (230.9) 255.9 (236.1) 130.4 (167.9) 0.2 (0.1)
Alpha-lactalbumin, kUA/l(SD) 6 (11.2) 0.6 (0.7) 3.1 (3.9) –
Beta-lactoglobulin, kUA/l(SD) 4.5 (7.1) 2.2 (3.4) 1.9 (2.6) –
Bovine serum albumin, kUA/l(SD) 5.4 (8.7) 0.9 (1.8) 1.9 (3) –
nBCasein, kUA/l(SD) 22.7 (39.2) 0.5 (0.4) 1.3 (2.7) –
Lactoferrin, kUA/l(SD) 2 (6.1) 0 0 –
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+ LGG-based treatment, and group 3 patients received the
following formulas: EHCF (n = 3), soy formula (SF, n = 3),
amino acid-based formula (AAF, n = 3), hydrolyzed rice
formula (RHF, n = 1). The median duration of dietother-
apy was 384 days (IQR 7.75) in both groups.
As shown in Fig. 1a, the rate of FoxP3 TSDR demeth-
ylation was lower in active IgE-mediated CMA patients
(group 1) than in healthy controls (1.3 ± 1.3 vs 20 ± 2.1,
P < 0.0001). To determine the fold expression levels, we
normalized FoxP3 TSDR expression vs the transcription
levels of the housekeeping gene GUS in the four study
groups. As shown in Fig. 1b, FoxP3 expression was sig-
nificantly lower (P < 0.0001) in active IgE-mediated
CMA children than in healthy controls. Moreover, it
Fig. 1 FoxP3 TSDR demethylation rate (%) (a) and FoxP3 mRNA expression versus GUS expression (b) observed in study groups (group 1, CMA
children at diagnosis; group 2, children outgrown CMA after treatment with EHCF + LGG; group 3, children outgrown CMA after treatment with
other formulas; group 4, healthy controls)
Fig. 2 Linear regression analysis of % FoxP3 TSDR demethylation rate (%) in PBMCs versus FoxP3 mRNA expression in study subjects
Paparo et al. Clinical Epigenetics  (2016) 8:86 Page 4 of 6
was higher in children who outgrew CMA than in
children with active IgE-mediated CMA, but similar to
levels in the healthy children. The FoxP3 TSDR
demethylation rate was correlated with FoxP3 expression
levels (Fig. 2). Notably, the FoxP3 TSDR demethylation
profile stratified CMA patients according to disease state.
In fact, the demethylation profile in subjects with recent
evidence of tolerance acquisition was different to that of
active CMA patients and differed significantly (P < 0.0001)
between children treated with EHCF + LGG and children
receiving other formulas (Fig. 1a).
Discussion
Our data show that tolerance acquisition in children
with IgE-mediated CMA involves epigenetic regulation
of the FoxP3 gene. We found that FoxP3 TSDR demeth-
ylation is significantly increased in CMA children who
acquired oral tolerance. Similarly, it has been demon-
strated that farm milk exposure in children has an al-
lergy preventive effect which is linked to FoxP3 TSDR
demethylation in peripheral blood cells [19].
We found a significant difference in the methylation
status of FoxP3 TSDR gene comparing patients who ac-
quired oral tolerance after treatment with EHCF + LGG
vs children treated with other formulas. Similar results
have been observed investigating Th1/Th2 cytokines [2].
A recent study showed that LGG in addition to vitamin
D supplementation increased the number of CD4+CD25
+FoxP3+ Treg in children with allergic rhinitis [21].
We demonstrated that EHCF + LGG but not EHCF
alone is able to positively shape gut microbiota compos-
ition increasing the abundance of butyrate-producer
bacteria strains [22]. Butyrate is able to inhibit histone
deacetylase 9 and 6 with subsequent demethylation of
Foxp3 gene [23]. Finally, a formula-induced regulation of
circulating miRNAs (microRNA-155, microRNA-148a,
microRNA-29b, microRNA-21) acting on Treg differen-
tiation may be also involved [24].
Although with various caveats (the use of PBMCs, a
cross-sectional design, and the relatively low number of
subjects), our study sheds light on how variations in the
level of FoxP3 TSDR demethylation can affect the course
of CMA and demonstrates that dietary intervention
influences this epigenetic mechanism. Our results also
suggest that the FoxP3 TSDR demethylation rate could
serve as a biomarker of oral tolerance. The novel data
reported herein may serve as a basis for the develop-
ment of new diagnostic and therapeutic tools for CMA.
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